Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EIF4E2, also called eIF4E-homologous protein (4EHP), is a member of the eukaryotic translation initiation factor 4E family. It binds the 7-methylguanosine cap of mRNA and acts primarily as a repressor of translation initiation. Unlike canonical eIF4E, EIF4E2 does not bind eIF4G, thereby inhibiting assembly of the eIF4F complex and blocking cap-dependent translation. It participates in RNA silencing pathways, regulates the translation of certain stress- and interferon-responsive genes, and is involved in the response to viral infection by controlling innate immune responses. EIF4E2 is not a widely accepted drug target, nor is it a pseudogene as implied by the original query.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 4E family member 2 (EIF4E2).